Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impact on Diagnosis, Prognosis, and Therapeutic Target

Version 1 : Received: 31 December 2021 / Approved: 19 January 2022 / Online: 19 January 2022 (12:13:03 CET)
Version 2 : Received: 7 February 2022 / Approved: 9 February 2022 / Online: 9 February 2022 (12:59:34 CET)

How to cite: Giordano, G.; Ferioli, E.; Tafuni, A. The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impact on Diagnosis, Prognosis, and Therapeutic Target. Preprints 2022, 2022010271 (doi: 10.20944/preprints202201.0271.v1). Giordano, G.; Ferioli, E.; Tafuni, A. The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impact on Diagnosis, Prognosis, and Therapeutic Target. Preprints 2022, 2022010271 (doi: 10.20944/preprints202201.0271.v1).

Abstract

Mesothelin is a protein that is expressed in the mesothelial cell lining in the pleura, peritoneum and pericardium. The gene of mesothelin encodes a precursor protein that is processed to yield mesothelin, which is attached to the cell membrane by a glycophosphatidylinositol linkage and a shred fragment named the megakaryocytic-potentiating factor. The biological functions of this substance in normal cells are still unknown. Experimental studies on knockout mice suggest that this substance does not play an important role in development and reproduction. In contrast, it has been observed that mesothelin is produced in abnormal amounts in several malignant neoplasms such as mesotheliomas and pancreatic adenocarcinomas. Given that mesothelin is overexpressed in many solid tumours and has antigenic properties, this molecule could be considered a tumour marker or an antigenic target for many malignancies. Many molecular studies also have demonstrated that mesothelin is overexpressed in serous ovarian carcinomas and may bind to ovarian cancer antigen Ca-125, favouring the spread of the tumour in the abdominal cavity. Here, we discuss the current knowledge of mesothelin and focus on its role in clinical and pathological diagnoses as well as its impact on the prognosis in serous ovarian carcinomas. We also briefly discuss the latest progress of mesothelin-targeting therapies for this aggressive and lethal neoplasm.

Keywords

Mesothelin; serous ovarian carcinoma; target Therapies

Subject

LIFE SCIENCES, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.